mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation
Article in Frontiers in Oncology (January 2024)
The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.
Article in Frontiers in Oncology (January 2024)
Article in Journal of Clinical Medicine (November 2023)
Article in International Journal of Molecular Sciences (November 2023)